| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1346756 | Tetrahedron: Asymmetry | 2010 | 7 Pages |
A novel family of tetrahydroisoquinoline (TIQ) phosphine–oxazoline ligands and four corresponding iridium complexes have been developed and applied to the asymmetric hydrogenation of unfunctionalized olefins. The results showed that the best conversion rates were observed in up to 99% with an enantiomeric excess of 91%.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
(S)-Benzyl 3-((R)-2-hydroxy-1-phenylethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC26H26N2O4[α]D20=-26.2 (c 0.42, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3R)
(S)-Benzyl 3-((S)-2-hydroxy-1-phenylethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC26H26N2O4[α]D20=+10.7 (c 0.70, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3S)
(S)-Benzyl 3-((R)-1-hydroxy-3-methylbutan-2-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC23H28N2O4[α]D20=+4.4 (c 0.80, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3R)
(S)-Benzyl 3-((S)-1-hydroxy-3-methylbutan-2-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC23H28N2O4[α]D20=23.1 (c 1.17, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3S)
(S)-Benzyl 3-((R)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC26H24N2O3[α]D20=+2.7 (c 0.37, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3R)
(S)-Benzyl 3-((S)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC26H24N2O3[α]D20=+12.2 (c 0.41, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3S)
(S)-Benzyl 3-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC23H26N2O3[α]D20=+3.4 (c 0.89, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3R)
(S)-Benzyl 3-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylateC23H26N2O3[α]D20=9.7 (c 0.72, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,3S)
(R)-4-Phenyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazoleC18H18N2O[α]D20=+46.15 (c 0.26, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1R,2S)
(S)-4-Phenyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazoleC18H18N2O[α]D20=7.4 (c 1.85, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,2S)
(R)-4-Isopropyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazoleC15H20N2O[α]D20=12.7 (c 0.55, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1R,2S)
(S)-4-Isopropyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazoleC15H20N2O[α]D20=10.9 (c 0.69, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,2S)
(η4-1,5-Cyclooctadiene) (R)-2-((S)-2-(diphenylphosphino)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-phenyl-4,5-dihydrooxazole iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borateC70H51BN2PF24OIr[α]D20=3.1 (c 0.32, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1R,2S)
(η4-1,5-Cyclooctadiene) (S)-2-((S)-2-(diphenylphosphino)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-phenyl-4,5-dihydrooxazole iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borateC70H51BN2PF24OIr[α]D20=+40.9 (c 1.15, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,2S)
(η4-1,5-Cyclooctadiene) (R)-2-((S)-2-(diphenylphosphino)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-isopropyl-4,5-dihydrooxazole iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borateC67H53BN2PF24OIr[α]D20=+1.6 (c 0.64, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1R,2S)
(η4-1,5-Cyclooctadiene) (S)-2-((S)-2-(diphenylphosphino)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-isopropyl-4,5-dihydrooxazole iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borateC67H53BN2PF24OIr[α]D20=+30.2 (c 0.86, CH2Cl2)Source of chirality: l-phenylalanineAbsolute configuration: (1S,2S)
